Eric Reynolds, NP
Family · Vernal, UTNPI 1710311279
Payments from drug & device makers
Across 162 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$455
- Boehringer Ingelheim$190
- Novo Nordisk$172
- Lilly USA, LLC$147
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$109
- plus $910 from 19 others
What the payments were for
- Food & beverage$3,090100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,115 |
| AbbVie | 30 | $455 |
| Boehringer Ingelheim | 9 | $190 |
| Novo Nordisk | 10 | $172 |
| Lilly USA, LLC | 8 | $147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $109 |
| Xeris Pharmaceuticals, Inc. | 6 | $98 |
| Krystal Biotech Inc | 2 | $92 |
| Merck | 5 | $85 |
| Gilead | 3 | $81 |
| Corcept Therapeutics | 3 | $70 |
| Lundbeck LLC | 3 | $62 |
| Pfizer | 3 | $59 |
| Abbott | 3 | $49 |
| Dexcom, Inc. | 3 | $46 |
| Indivior Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $38 |
| Braeburn Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Johnson & Johnson | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| GSK | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
How this compares
$3,097 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 39 | $281,821 |
| FarxigaDapagliflozin Propanediol | 144 | $227,307 |
| JanuviaSitagliptin Phosphate | 80 | $132,303 |
| JardianceEmpagliflozin | 59 | $104,776 |
| OzempicSemaglutide | 82 | $96,389 |
| EliquisApixaban | 66 | $95,869 |
| XareltoRivaroxaban | 42 | $65,125 |
| ByettaExenatide | 25 | $34,798 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $31,308 |
| MounjaroTirzepatide | 22 | $30,332 |
| TrulicityDulaglutide | 17 | $16,274 |
| LinzessLinaclotide | 18 | $15,066 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,041 |
| Levemir FlexpenInsulin Detemir | 34 | $10,347 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $9,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Byetta, Symbicort | $1,115 | $268,859188 claims |
| MerckJanuvia, Janumet | $85 | $163,611100 claims |
| Boehringer IngelheimJardiance | $190 | $104,77659 claims |
| Novo NordiskOzempic | $172 | $96,38982 claims |
| PfizerEliquis | $59 | $95,86966 claims |
| Johnson & JohnsonXarelto | $26 | $65,12542 claims |
| Lilly USA, LLCMounjaro, Trulicity | $147 | $46,60639 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $18 | $15,53822 claims |
| AbbVieLinzess | $455 | $15,06618 claims |
| Indivior Inc.Suboxone | $46 | $2,91411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.
Other family in Vernal
- Annemarie RousseauVernal$12K
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.